创伤患者谵妄预防的药物干预:随机对照试验的系统评价与网状Meta分析
该研究检索MEDLINE、Embase和Cochrane临床试验注册库(自建库至2022年6月7日),纳入比较危重症创伤患者药物干预的随机对照试验,最终纳入6项RCT(n=382例)。采用贝叶斯网状Meta分析,以HR(二分类结局)和均数差(连续结局)及95%可信区间进行组间比较。与丙泊酚-右美托咪定联合相比,右美托咪定(HR 1.44,95%CI 0.39-6.94)、丙泊酚(HR 2.38,95%CI 0.68-11.36)或氟哌啶醇(HR 3.38,95%CI 0.65-21.79)的谵妄发生率可能无差异;与单用右美托咪定相比,丙泊酚(HR 1.66,95%CI 0.79-3.69)或氟哌啶醇(HR 2.30,95%CI 0.88-6.61)可能无效应。作者结论为创伤ICU患者中药物干预在谵妄发生、ICU住院时间、住院时间或死亡率上未发现差异。
要点
- 纳入6项RCT共382例危重症创伤患者,比较药物预防谵妄的网状Meta分析。
- 与丙泊酚-右美托咪定联合相比,右美托咪定(HR 1.44,95%CI 0.39-6.94)、丙泊酚(HR 2.38,95%CI 0.68-11.36)、氟哌啶醇(HR 3.38,95%CI 0.65-21.79)的谵妄发生率可能无差异。
- 与单用右美托咪定相比,丙泊酚(HR 1.66,95%CI 0.79-3.69)或氟哌啶醇(HR 2.30,95%CI 0.88-6.61)可能无效应。
- 作者结论:创伤ICU患者中药物干预在谵妄发生、ICU住院时间、住院时间或死亡率上未发现差异。
适用人群与场景
- 危重症创伤患者(ICU创伤患者),纳入比较药物干预预防谵妄的随机对照试验。
研究设计与关键结果
- 研究类型:系统评价与网状Meta分析(随机对照试验),检索MEDLINE、Embase和Cochrane临床试验注册库自建库至2022年6月7日,共筛选3541条引文,纳入6项RCT(n=382例患者)。
- 与丙泊酚-右美托咪定联合相比,右美托咪定(HR 1.44,95%CI 0.39-6.94)、丙泊酚(HR 2.38,95%CI 0.68-11.36)、氟哌啶醇(HR 3.38,95%CI 0.65-21.79)的谵妄发生率可能无差异。
- 与单用右美托咪定相比,丙泊酚(HR 1.66,95%CI 0.79-3.69)或氟哌啶醇(HR 2.30,95%CI 0.88-6.61)可能无效应。
- 作者结论:创伤ICU患者中药物干预在谵妄发生、ICU住院时间、住院时间或死亡率上未发现差异。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与网状Meta分析;采用贝叶斯随机效应模型,遵循PRISMA网状Meta分析指南;治疗排名以累积排序曲线下面积(SUCRA)值表示。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论提示创伤ICU患者中药物干预在谵妄发生、ICU住院时间、住院时间或死亡率上未发现差异,原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To compare the relative efficacy of pharmacologic interventions in the prevention of delirium in ICU trauma patients.
DATA SOURCES: We searched Medical Literature Analysis and Retrieval System Online, Embase, and Cochrane Registry of Clinical Trials from database inception until June 7, 2022. We included randomized controlled trials comparing pharmacologic interventions in critically ill trauma patients.
STUDY SELECTION: Two reviewers independently screened studies for eligibility, extracted data, and assessed risk of bias.
DATA EXTRACTION: Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines for network analysis were followed. Random-effects models were fit using a Bayesian approach to network meta-analysis. Between-group comparisons were estimated using hazard ratios (HRs) for dichotomous outcomes and mean differences for continuous outcomes, each with 95% credible intervals. Treatment rankings were estimated for each outcome in the form of surface under the cumulative ranking curve values.
DATA SYNTHESIS: A total 3,541 citations were screened; six randomized clinical trials (n = 382 patients) were included. Compared with combined propofol-dexmedetomidine, there may be no difference in delirium prevalence with dexmedetomidine (HR 1.44, 95% CI 0.39-6.94), propofol (HR 2.38, 95% CI 0.68-11.36), nor haloperidol (HR 3.38, 95% CI 0.65-21.79); compared with dexmedetomidine alone, there may be no effect with propofol (HR 1.66, 95% CI 0.79-3.69) nor haloperidol (HR 2.30, 95% CI 0.88-6.61).
CONCLUSIONS: The results of this network meta-analysis suggest that there is no difference found between pharmacologic interventions on delirium occurrence, length of ICU stay, length of hospital stay, or mortality, in trauma ICU patients.
参考来源
- Zitikyte G, Roy DC, Tran A, et al. Pharmacologic Interventions to Prevent Delirium in Trauma Patients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Crit Care Explor. 2023. PMID: 36937896. doi:10.1097/CCE.0000000000000875
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。